Trump Signs Executive Order to Expedite Psychedelic Drug Reviews, Including Ibogaine
President Donald Trump signed an executive order to accelerate the review of psychedelic drugs, including ibogaine, which is classified as a high-risk substance. The move aims to speed up medical research and clinical trials for these drugs, which have shown potential in treating conditions like PTSD and opioid addiction. The administration claims this could have a significant impact if the drugs prove effective.
Topics: FDA ibogaine medical research President Trump psychedelic drugs regulatory change